Highlights
- Record quarterly cash receipts of $8.1 million, up over 50% on previous quarter and over 20% on previous corresponding period
- Record quarterly revenue of $7.3 million (unaudited), up 34% on previous quarter and over36% on previous corresponding period
- Record revenue of $25.6million (unaudited) for FY24, up nearly 30% on previous financial year resulting in positive operating cashflow of $0.5million for financial year
- Cannabis legalised in Germany with its removal from the Narcotics List
- Cash in bank of $5.0 million at 31 March 2024 up from $3.7 million at 31 December 2023
To view a copy of the company’s Quarterly Activities Report lease click here
About Little Green Pharma
Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.
The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.
Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.
The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.
